Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Aim Immunotech Inc (AIM)

Aim Immunotech Inc (AIM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
AIM ImmunoTech Announces Positive Progress on Requested FDA Meeting for Proposed Ampligen Clinical Trial in Post-COVID-19 Cognitive Dysfunction

AIM ImmunoTech Inc. (NYSE American: AIM) today announced positive progress with the company's meeting request to the U.S. Food and Drug Administration (FDA) concerning a Phase 2 clinical study of Ampligen...

AIM : 1.97 (-4.83%)
AIM ImmunoTech Provides an Update on Its Pending Phase 2a Human Challenge Trial Using its Drug Ampligen

AIM ImmunoTech Inc. (NYSE American: AIM) today provided a status update on its Phase 2a Human Challenge Trial (HCT) to test the company's drug Ampligen as a potential intranasal prophylactic therapy using...

AIM : 1.97 (-4.83%)
TRADE X acquires automotive export specialist Techlantic

Automotive trade platform TRADE X has acquired vehicle export specialist Techlantic after raising $45 million over the summer.

AIM : 1.97 (-4.83%)
AIM ImmunoTech Announces Filing of Provisional Patent Application for Use of Ampligen as Both an Intranasal and an IV Therapy for Post-COVID-19 Cognitive Dysfunction (PCCD)

AIM ImmunoTech Inc. (NYSE American: AIM) today provided an update on the company's efforts to develop its drug Ampligen as a potential intranasal therapeutic for COVID-19, including the announcement of...

AIM : 1.97 (-4.83%)
2 Biotech Stocks Focused on Fighting the Coronavirus that Could Double in Price

As the rapid spread of the COVID-19 Delta variant continues to disrupt several economies, there is growing concern about the virus’ potential long-term physical effects. Given this backdrop, which suggests...

HGEN : 6.39 (unch)
AIM : 1.97 (-4.83%)
AIM ImmunoTech Provides Second Quarter 2021 Business Update

AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the second quarter ended June 30, 2021 and provides a business update.

AIM : 1.97 (-4.83%)
AIM CEO Thomas K. Equels Named to Board of Directors of BioFlorida Inc.

AIM ImmunoTech Inc. (NYSE American: AIM) today announced that CEO Thomas K. Equels has been appointed to the Board of Directors of BioFlorida Inc., the state's life sciences industry association.

ADMA : 1.2400 (-0.80%)
SRTSU : 6.45 (-0.77%)
AIM : 1.97 (-4.83%)
AIM ImmunoTech Announces Phase 2a Human Challenge Trial to Test its Drug Ampligen as an Intranasal Antiviral Prophylactic Therapy

AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has signed a contract to sponsor a Phase 2a Human Challenge Trial (HCT) to test the company's drug Ampligen as a potential intranasal antiviral...

AIM : 1.97 (-4.83%)
ORPH : 4.57 (+1.56%)
AIM ImmunoTech to Host Investor Update Webcast on Wednesday, July 14th at 11:00 AM ET

AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it will host an investor update webcast at 11:00 a.m. Eastern Time on Wednesday, July 14, 2021, to discuss recent accomplishments and upcoming...

AIM : 1.97 (-4.83%)
AIM ImmunoTech Completes All Treatments in Phase 1 Human Safety Study of Intranasal Administration of Ampligen

AIM ImmunoTech Inc. (NYSE American: AIM) today announced that all subjects have completed treatment in the Company's Phase 1 clinical study to assess the safety, tolerability and biological activity of...

AIM : 1.97 (-4.83%)

Barchart Exclusives

Palladium- A Shooting Star Became a Falling Knife
Gravity hit the palladium market like a ton of bricks over the past weeks, with the price falling below technical support levels as a hot knife goes through butter. Palladium is falling as a semiconductor shortage has caused demand from the automobile sector to decline over the past months. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar